Download Ingen bildrubrik

REGIONAL AND INTRAREGIONAL CLUSTERS
NOVUM RESEARCH PARK
1972
Huddinge University Hospital
1985-91
Novum Research Foundations
Center for Biotechnology
Center for Nutrition & Toxicology
Center for Structural Biochemistry
Center for Oral Biology
1985 -
Founders:
Stockholm County Council & Karolinska Institute
Purpose:
To create a biomedical center of excellence
R&D companies in and near Novum. Expanison of research
Improvements of infrastructure (communications, hotel, shops)
1989
Novum Research Center
1997 - 02 University of Södertörn
2000 -
Planning for Novum BioCity
NOVUM RESEARCH PARK A.D. 2002
A qualified environment for front-line research
and for the establishment and growth of research-based
companies
Novum Research Foundations
(4 foundations ~ 350 employees) biomedical basic research
Departments & Centers of Research (~ 350 employees)
Karolinska Institute, Huddinge University Hospital,
Södertörn University
biomedical & medical technology research
Research Companies (20 companies, ~ 450 employees)
Novum Business Development Group
business counselling, strategic planning
information & visitor’s service
NOVUM
PRECLINICAL RESEARCH
•
•
•
•
•
•
Nuclear receptors
Signal transduction
Molecular genetics
Molecular nutrition
Molecular immunology
Structural biochemistry
NOVUM
CLINICAL RESEARCH
• Cancer
Osteoporosis
• Metabolic disorders
Alzheimer’s disease
• Cellular therapy
Virus infection
• Gene therapy
(Hepatitis)
NEIGHBOURS AND PARTNERS IN
NOVUM RESEARCH PARK
• HUDDINGE UNIVERSITY HOSPITAL
• THE KAROLINSKA INSTITUTET MEDICAL SCHOOL
• SÖDERTÖRN UNIVERSITY COLLEGE
• SERVICE COMPANIES (about 25)
_______________________
Appr. 17.000 personer (employees & students)
working daily in the park area
BUSINESS COUNSELLING
IN NOVUM
•Patenting
•Licensing
•Business law
•Market analysis
•Business Planning
•Financing
NOVUM’S
RESEARCH COMPANIES
Multinationals
AstraZeneca
Pain Control Research
Baxter Medical
Renal Function Research
Sumitomo Pharmaceuticals Alzheimer’s disease
Novum’s
Research Companies
R&D specialists
Karo Bio
Receptor biology
Medivir
HIV & Herpes antivirals
Tripep
HIV antivirals
LightUp Technologies
DNA probe technology /diagnostics
Avaris
Gene vector technolog
Oxypharma
Rheumatoid Arthritis
NOVUM’S RESEARCH COMPANIES
Service & Technology providers
• CyberGene
• Nova Snitt Analysis
• SciBase
• Innomed-Konsult
Sequencing, genetic
diagnostics
Histology
Impedance analysis of skin
& mucosa
Design of GMP facilities
NOVUM BIOCITY
NOVUM BIOCITY
NOVUM RESEARCH PARK
Nuclear Receptors
Hormones or
Metabolic
Intermediates
Changed
Cell Function
Protein
Nuclear
Receptor
Target gene
•
Large family of receptors
• Important drugs on the
market
•
Validated drug targets
• Bind hormones with high
affinity
•
New technology and receptors
offer improved treatments and
new indications
LXR
New Promising Target for Atherosclerosis
• Upregulates cholesterol
pump (ABCA1)
• Upregulates APO-E in
macrophages
• Upregulates 7hydroxylase (cholesterol
break down)
LXR Concept to Treat Atherosclerosis
Drug compound
Atherosclerosis
stimulates
LXR activity
LXR stimulates
synthesis of
ABC1 protein
LXR
+
ABC1-protein
Cell
Treated
blood
vessel
Tangier disease; non-functional
ABC-1 leads to atherosclerosis
ABC1
removes
harmful
cholesterol
Karo Bio – Leader in Nuclear Receptor
and Proteomics-Based Drug Discovery
Boehringer Ingelheim
BMS
Merck
AHP
Abbott
Karo Bio AB
Stockholm
Karo Bio USA, Inc.
Durham, NC
Karo Bio, Inc.
San Francisco
Bayer AG
GPC Biotech
NovImmune S.A.
Serono International
Aventis
Business Concept
 Develop pharmaceuticals for major markets
 Be a leading company within the field of
nuclear receptors and proteomics-based drug
discovery
 Conduct clinical development and marketing
through partners and licensees
 Finance operations through partnerships
Revenue Model of Karo Bio
Up-front
payment
Target
identification
Research
funding
Drug
discovery
Pre-clinical
development
R&D
milestones
Clinical
development
Royalty
on sales
Market
Strategic Position
KARO BIO
Scientific
network
Karolinska Insitutet
UCSF
Duke University
University of Bochum
Sahlgrenska Hospital
University of York
…
Partners
Abbott Laboratories
Bristol-Myers Squibb
Merck & Co, Inc.
Aventis
…
Nuclear Receptor Project Portfolio
Target and
indication Drug discovery Preclinical
Development
validation
LXR
AHP
R Prostate cancer
/KB
MR Heart failure
/KB
GR Inflammation
/KB
ER
Merck
…...C l i n i c a l D e v e l o p m e n t…...
Phase I
Phase II
Phase III
THR
2 1 1 Obesity
BMS
2
GR
Diabetes
Abbott
THR CardiacTHR
015/Cardiac
arrhythmia /KB
arrhythmia/KB
THR
Glaucoma/KB
Anti-microbials/KB
THR
KB2611/
Skin atrophy /KB
NDA
Karo Bio has a diverse nuclear
receptor research portfolio
Disease
area
Drug discovery
Preclinical
development
Clinical development
Phase I Phase II Phase III
NDA/
Market
100 MUSD
+ Royalties
Oestrogen
receptor
80 MUSD
+ Royalties
Type II
diabetes
56 MUSD
+ Royalties
Obesity
40 MUSD
+ Royalties
Atherosclerosis
Karo Bio has four profitable nuclear receptor
collaborations in potential block-buster areas
Några reflektioner kring ett nytt
paradigm för medicinsk och
bioteknisk forskning
• Avståndet mellan laboratoriebänken och patientens
säng har minskat betydligt och minskar allt snabbare i
takt med den nya molekylärbiologiska forskningens
landvinningar
• Enda sättet att föra över forskningsresultat från
lab.bänken till patienten går via patentering och
kommersialisering
• Den nutida laboratorieforskaren har ett etiskt
imperativ att börja arbeta i denna riktning (modern
tillämpning av den Hippokratiska eden!)
Några reflektioner…… (forts.)
• Det nya paradigmet för medicinsk/naturvetenskaplig
forskning består i en trestegsraket, akademi, SMEs
samt stora företag, där de två första stegen bör
samlokaliseras under ett tak
• I detta cluster kommer nya forskningsstrategier och
forskningstekniker att växa fram samtidigt som nya
utbildningslinjer med kombinationer av bioteknik,
medicin, ekonomi, juridik, etik mm kommer att
utvecklas
• Allt detta betyder effektivare forskning, större
konkurrenskraft i ett internationellt perspektiv samt
bättre ekonomi för Sverige